NCT06241807 2024-02-14
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
Clinical Trials
4 trialsNCT05841472 2023-08-30
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
CrystalGenomics, Inc.
Phase 2 Recruiting
NCT05825443 2023-04-25
PANORAMA
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT05053802 2021-09-23
MAGIC
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting